📣 VC round data is live. Check it out!

Revenio Group Valuation Multiples

Discover Revenio Group's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Medistim, Kamada, Imricor Medical Systems, Standard BioTools and more.

Revenio Group Overview

About Revenio Group

Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for detecting diseases of significance to public health. Its ophthalmic diagnostic solutions includes intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, USA, and Others.


Founded

2001

HQ

Finland

Employees

241

Financials (LTM)

Revenue: $149M
EBITDA: $38M

EV

$425M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Revenio Group Financials

Revenio Group reported last 12-month revenue of $149M and EBITDA of $38M.

In the same LTM period, Revenio Group generated $79M in gross profit, $38M in EBITDA, and $21M in net income.

Revenue (LTM)


Revenio Group P&L

In the most recent fiscal year, Revenio Group reported revenue of $130M and EBITDA of $37M.

Revenio Group is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 28%, and net margin of 16%.

See analyst estimates for Revenio Group
LTMLast FY202320242025202620272028
Revenue$149M$130M$112M$120M$128M
Gross Profit$79M$91M$79M$85M$91M
Gross Margin53%70%71%70%71%
EBITDA$38M$37M$35M$35M$32M
EBITDA Margin25%28%31%29%25%
EBIT Margin21%24%27%24%23%
Net Profit$21M$21M$22M$22M$20M
Net Margin14%16%20%18%16%

Financial data powered by Morningstar, Inc.

Revenio Group Stock Performance

Revenio Group has current market cap of $445M, and enterprise value of $425M.

Market Cap Evolution


Revenio Group's stock price is $15.29.

Revenio Group share price decreased by 6.1% in the last 30 days, and by 52.2% in the last year.

Revenio Group has an EPS (earnings per share) of $0.72.

See more trading valuation data for Revenio Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$425M$445M-1.2%-6.1%-31.7%-52.2%$0.72

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Revenio Group Valuation Multiples

Revenio Group trades at 2.9x EV/Revenue multiple, and 11.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Revenio Group

EV / Revenue (LTM)


Revenio Group Financial Valuation Multiples

As of June 3, 2026, Revenio Group has market cap of $445M and EV of $425M.

Revenio Group has a P/E ratio of 21.1x.

LTMLast FY202320242025202620272028
EV/Revenue2.9x3.3x3.8x3.5x3.3x
EV/EBITDA11.3x11.6x12.2x12.0x13.2x
EV/EBIT13.5x13.6x13.9x14.6x14.4x
EV/Gross Profit5.4x4.7x5.4x5.0x4.7x
P/E21.1x21.3x20.0x20.7x22.0x
EV/FCF17.5x14.0x53.9x18.6x14.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Revenio Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Revenio Group Margins & Growth Rates

Revenio Group grew revenue by 34% and EBITDA by 8% in the last fiscal year.

In the most recent fiscal year, Revenio Group reported gross margin of 70%, EBITDA margin of 28%, and net margin of 16%.

See estimated margins and future growth rates for Revenio Group

Revenio Group Margins

Last FY202420252026202720282029
Gross Margin70%70%71%57%
EBITDA Margin28%29%25%23%
EBIT Margin24%24%23%18%
Net Margin16%18%16%12%
FCF Margin23%19%24%11%

Revenio Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth34%7%6%36%
Gross Profit Growth10%7%7%10%
EBITDA Growth8%1%(9%)23%
EBIT Growth1%(5%)1%7%
Net Profit Growth3%(3%)(6%)6%
FCF Growth(39%)190%32%(39%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Revenio Group Operational KPIs

Revenio Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Revenio Group's Rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Revenio Group's Rule of X is 113% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Revenio Group
LTMLast FY202320242025202620272028
Rule of 4056%59%---
Bessemer Rule of X101%113%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue-5%5%6%5%
G&A Expenses to Revenue8%8%8%7%8%
R&D Expenses to Revenue2%2%3%3%2%
Opex to Revenue-47%43%46%48%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Revenio Group Competitors

Revenio Group competitors include Medistim, Kamada, Imricor Medical Systems, Standard BioTools, AngioDynamics, Tess Holdings Co, OrthoPediatrics, Medmix, Vicenne and The Beauty Tech Group.

Most Revenio Group public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medistim5.6x5.5x16.6x18.2x
Kamada2.1x2.0x9.1x8.3x
Imricor Medical Systems1456.5x264.3x(19.8x)(18.9x)
Standard BioTools0.3x0.3x(0.4x)(0.6x)
AngioDynamics1.4x1.3x54.4x33.3x
Tess Holdings Co3.7x3.0x25.3x-
OrthoPediatrics2.0x1.9x32.8x25.2x
Medmix1.3x1.3x6.8x6.7x

This data is available for Pro users. Sign up to see all Revenio Group competitors and their valuation data.

Start Free Trial

Acquisitions by Revenio Group

Revenio Group has acquired 2 companies to date.

Last acquisition by Revenio Group was on April 12th 2026. Revenio Group acquired VISIONIX for $336M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Revenio Group

VISIONIX
Oculo
Description
VISIONIX is a U.S.-headquartered manufacturer of ophthalmic equipment leveraging patented PowerMap technology for multipoint lens measurements based on Hartmann wavefront analysis. The company supplies refractometers, edgers, and polishers to optometrists, opticians, and labs worldwide, maintaining a partnership with Briot International since 2010 for integrated workflow solutions.
Oculo is a digital health platform connecting optometrists and ophthalmologists across Australia to collaborate on patient care. The Sydney-based company facilitates seamless sharing of patient records, referral management, and treatment planning through its web portal at connect.oculo.com.au. Launched to address fragmented eye care workflows, Oculo streamlines communications between primary eye care providers and specialists, improving diagnosis accuracy and patient outcomes in the country's public and private clinics.
HQ CountryIsraelUnited Kingdom
HQ City
Jerusalem
York
Deal Date12 Apr 202619 Mar 2021
Valuation$336M$12M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Revenio Group acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Revenio Group

When was Revenio Group founded?Revenio Group was founded in 2001.
Where is Revenio Group headquartered?Revenio Group is headquartered in Finland.
How many employees does Revenio Group have?As of today, Revenio Group has over 241 employees.
Who is the CEO of Revenio Group?Revenio Group's CEO is Jouni Toijala.
Is Revenio Group publicly listed?Yes, Revenio Group is a public company listed on Nasdaq Helsinki.
What is the stock symbol of Revenio Group?Revenio Group trades under REG1V ticker.
When did Revenio Group go public?Revenio Group went public in 2001.
Who are competitors of Revenio Group?Revenio Group main competitors include Medistim, Kamada, Imricor Medical Systems, Standard BioTools, AngioDynamics, Tess Holdings Co, OrthoPediatrics, Medmix, Vicenne, The Beauty Tech Group.
What is the current market cap of Revenio Group?Revenio Group's current market cap is $445M.
What is the current revenue of Revenio Group?Revenio Group's last 12 months revenue is $149M.
What is the current revenue growth of Revenio Group?Revenio Group revenue growth (NTM/LTM) is 30%.
What is the current EV/Revenue multiple of Revenio Group?Current revenue multiple of Revenio Group is 2.9x.
What is the current EBITDA of Revenio Group?Revenio Group's last 12 months EBITDA is $38M.
What is Revenio Group's EBITDA margin?Revenio Group's last 12 months EBITDA margin is 25%.
What is the current EV/EBITDA multiple of Revenio Group?Current EBITDA multiple of Revenio Group is 11.3x.
What is the current FCF of Revenio Group?Revenio Group's last 12 months FCF is $24M.
What is Revenio Group's FCF margin?Revenio Group's last 12 months FCF margin is 16%.
What is the current EV/FCF multiple of Revenio Group?Current FCF multiple of Revenio Group is 17.5x.
How many companies Revenio Group has acquired to date?As of June 2026, Revenio Group has acquired 2 companies.
What was the largest acquisition by Revenio Group?$336M acquisition of VISIONIX on 12th April 2026 was the largest M&A Revenio Group has done to date.
What companies Revenio Group acquired?Revenio Group acquired VISIONIX and Oculo.
In how many companies Revenio Group has invested to date?Revenio Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Revenio Group

Lists including Revenio Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial